Market Overview

Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors

Share:

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that it has appointed
Scott Jackson, former Chief Executive Officer of Celator
Pharmaceuticals, Inc., to its Board of Directors. Mr. Jackson served as
Celator's CEO and as a member of its Board of Directors from April
2008 until July 2016, when the company was acquired by Jazz
Pharmaceuticals plc.

"As uproleselan advances in late-stage clinical trials in acute myeloid
leukemia (AML), Scott's experience leading Celator through the
successful development of Vyxeos® for treatment of newly
diagnosed AML patients will be invaluable to GlycoMimetics," said Rachel
King, GlycoMimetics' Chief Executive Officer. "His deep operational
experience, including in sales, marketing and commercialization, is
directly relevant as we look forward to potentially commercializing this
novel drug candidate."

Mr. Jackson has more than 25 years of experience in the pharmaceutical
and biotechnology industry and has held positions of increasing
responsibility in sales, marketing and commercial development at Eli
Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a
division of Johnson & Johnson, Eximias Pharmaceutical and YM
BioSciences. He holds a B.S. in pharmacy from the Philadelphia College
of Pharmacy and Science and an M.B.A. from the University of Notre
Dame. Mr. Jackson presently serves on the Board of Directors of
MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania
Chapter of The Leukemia and Lymphoma Society.

"I am excited to join the GlycoMimetics Board at a time when the company
is making tremendous strides in the development of glycomimetic
compounds, such as uproleselan for AML," said Mr. Jackson. "AML is an
area of high unmet medical need and uproleselan, if approved, could
potentially make a significant impact on the treatment of patients with
AML. I look forward to working with the Board and leadership team to
advance this important drug candidate and to leverage the potential of
the company's broad pipeline."

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics' most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate,
uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is currently being
evaluated in a company-sponsored Phase 3 trial in relapsed/refractory
AML. The U.S. Food and Drug Administration granted uproleselan
breakthrough therapy designation for the treatment of adult AM) patients
with relapsed/refractory disease. GlycoMimetics has also completed a
Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including
statements regarding the clinical development and potential utility of
the company's drug candidates. Actual results may differ materially from
those in these forward-looking statements. For a further description of
the risks associated with these statements, as well as other risks
facing GlycoMimetics, please see the risk factors described in the
company's quarterly report on Form 10-Q filed with the U.S. Securities
and Exchange Commission (SEC) on November 2, 2018, and other filings
GlycoMimetics makes with the SEC from time to time. Forward-looking
statements speak only as of the date of this release, and GlycoMimetics
undertakes no obligation to update or revise these statements, except as
may be required by law.

View Comments and Join the Discussion!